Bulk Inquiry
TAK 165
- Mubritinib
Axon 2053
CAS:
366017-09-6
Purity:
99%
- Soluble in DMSO
- MF: C25H23F3N4O2
- MW: 468.47
Description
Highly selective, potent and irreversible human epidermal growth factor receptor 2 (HER2 aka ErbB2) antagonist (IC50: 6 nM); recommended tool compound for HER2 selective inhibition
More Information
| Parent CAS No. | 366017-09-6 |
|---|---|
| Chemical Name | (E)-4-((4-(4-(1H-1,2,3-triazol-1-yl)butyl)phenyl1H-1,2,3-triazol-1-yl)butyl)phenoxy)methyl)-2-(4-(trifluoromethyl)styryl)oxazole |
| SMILES | C(=C/C1OC=C(COC2C=CC(CCCCN3C=CN=N3)=CC=2)N=1)C1C=CC(C(F)(F)F)=CC=1 |
| MFCD | MFCD09954135 |
| InChi | InChI=1S/C25H23F3N4O2/c26-25(27,28)21-9-4-20(5-10-21)8-13-24-30-22(18-34-24)17-33-23-11-6-19(7-12-23)3-1-2-15-32-16-14-29-31-32/h4-14,16,18H,1-3,15,17H2/b13-8+ |
| InChiKey | ZTFBIUXIQYRUNT-MDWZMJQESA-N |
| CID | 6444692 |
| Short Description | HER2 inhibitor |
References
- J Nagasawa et al. Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo. Int. J. Urol. 2006, 13(5), 587-592.
- JC Uitdehaag et al. A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets. Br. J. Pharmacol. 2012, 166, 858–876.
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 1395 | Lapatinib ditosylate |
From $88.00 |
| 1526 | Neratinib |
From $88.00 |
| 1537 | CP 724714 |
From $88.00 |
| 1544 | BIBW 2992 |
From $55.00 |
| 1653 | AEE 788 |
From $88.00 |
| 1986 | AST 1306 tosylate |
From $99.00 |
| 2560 | Tilfrinib |
From $104.50 |
| 3235 | Dacomitinib |
From $66.00 |
| 3853 | BMS-599626 |
From Inquiry |
| 4138 | CUDC-101 |
From Inquiry |
Other Categories
Get a Quote for
Loading...